all report title image
  • Published On : Sep 2022
  • Code : CMI5250
  • Industry : Pharmaceutical
  • Pages : 225
  • Formats :

There is no cure for dermatomyositis, but treatment can improve a patient’s skin and muscle strength and function. By treatment type, market is segmented by Anti-inflammatory medications, Immunosuppressive drugs, Immunoglobulin, and Others (Plasma Exchange, Monoclonal antibody among others). Some major factors involved in driving the market growth include development of novel treatment for the treatment of dermatomyositis by key players, increasing research and development for dermatomyositis and product launches by major players in market, increasing clinical trials by market players, and others.

Additionally, increasing funding by the government for clinical research is expected to propel the global dermatomyositis market over the forecast period. For instance, according to the data published by the Pharmaphorum in July 2022, the U.K government added US$ 212 million funding for clinical research, and to strengthen the national data infrastructure.

Global dermatomyositis market is estimated to be valued at US$ 493.15 million in 2022 and is expected to reach US$ 696.57 million by 2030, witnessing a CAGR of 4.4% over the forecast period (2022-2030).

Figure 1. Global Dermatomyositis Market Share (%), By Region, 2022

Dermatomyositis  | Coherent Market Insights

Increasing funding by non-profit organizations is expected to drive growth of the global dermatomyositis market.

The increasing number of research funding by governments and non-profit organizations of various countries for dermatomyositis or inflammatory myopathies treatment is expected to drive growth of the global dermatomyositis market over the forecast period.

For instance, in 2021, The Myositis Association, a non-profit organization dedicated to improving the lives of people affected by myositis, sponsoring creative research, and raising myositis awareness and activism, funded two research grants. A pilot study grant of US$ 200,000 had been provided to Dr. Kanneboyina Nagaraju, DVM, PhD of Binghamton University in New York.  Dr. Nagarahu’s research will focus on inflammatory muscle changes seen in Dermatomyositis and Polymyositis and their similarity to those seen in viral infections.  The study will evaluate whether this inflammation can be blocked using viral proteins. If successful, it could open up a new strategy for potential treatments.

Moreover, in May 2020, The Myositis Association (TMA) announced that recipients of the TMA's Innovative Research Grant, Professor Ian Hampson, Dr. Janine Lamb, and Dr. Spyridon Megremis at the University of Manchester had developed a novel approach to identify the targets of antibodies produced by the immune system in myositis patients. Dr. Lamb and the team analyzed antibodies and autoantibodies that accumulated throughout life in individuals with dermatomyositis, a rare autoimmune inflammatory muscle disease. Dermatomyositis is often marked by a distinctive skin rash and can affect both adults and children.

CMI table icon

Dermatomyositis Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 493.15 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 4.4% 2030 Value Projection: US$ 696.57 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Type: Adult Dermatomyositis, Dermatomyositis Sine Myositis , Juvenile (Childhood) Dermatomyositis (JDMS)
  • By Treatment Type: Anti-inflammatory Medication, Immunosuppressive Drugs, Immunoglobulin, Others (Plasma Exchange, Monoclonal antibody among others)
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

AstraZeneca Plc., Bristol-Myers Squibb Company, Octapharma AG, Corbus Pharmaceuticals Holdings, Inc., CSL Limited, Ermium Therapeutics, Kezar Life Sciences Inc., Mallinckrodt Plc., Néovacs, Horizon Therapeutics plc., and Pfizer Inc.

Growth Drivers:
  • Increasing funding by non-profit organizations for dermatomyositis or inflammatory myopathies treatment
  • Product approvals and launches for the treatment of dermatomyositis
Restraints & Challenges:
  • Side effects of dermatomyositis drugs

Figure 2. Global Dermatomyositis Market Share (%) Analysis, By Treatment Type, 2022

Dermatomyositis  | Coherent Market Insights

Increasing incidence of dermatomyositis is expected to drive growth of the global dermatomyositis market.

Increasing incidence of the juvenile dermatomyositis is expected to fuel the market growth over the forecast period. For instance, according to the data published by the Orphanet in March 2021, the annual incidence of Juvenile dermatomyositis (JDM) is 1 per 250,000-500,000 children. Females are affected more frequently than males (2-5:1 ratio).

Moreover, according to National Organization for Rare Disorders (NORD), 2021, the global incidence of dermatomyositis was estimated to be 9.63 cases per million people every year. The symptoms typically start to show in children between the ages of 5 and 15. Juvenile dermatomyositis affects approximately 3 in 1,000,000 children.

Global Dermatomyositis Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 outbreak in December 2019, the disease has spread to over 100 countries across the globe. The coronavirus (COVID 19) pandemic and consequent lockdown in various countries across the globe have impacted the financial status of businesses in all sectors. Supply chain and manufacturing activities have been disrupted globally, due to lockdowns implemented by governments of countries, restricted movement, and other COVID-19 safety precautions.

Moreover, the coronavirus pandemic has had a negative impact on the development, production, and supply of pharmaceutical products used in the treatment of various diseases in North America, Europe, and Asia Pacific. The supply and production of pharmaceutical products are affected due to the imposition of lockdown during the COVID-19 pandemic. This lockdown has resulted in the closure of industrial establishments, except the manufacturing of essential commodities, and disruption in the supply chain of pharmaceutical products.

Furthermore, according to ScienceDirect Journal, a journal of scientific publications, an article published in June 2021 about the impact of the COVID-19 pandemic on pharmaceutical systems and supply chains, the negative impact on the access and availability of essential medicines, particularly pharmaceutical products and antimicrobials, has been reported. Due to reduced inter-country transfer of products and services, as well as limited in-country capacity and manufacturing capabilities, most medical stores had extended lead times.

Global Dermatomyositis Market: Restraint

The drugs used for the treatment of dermatomyositis may cause some side effects or adverse events, which is expected to hinder the global dermatomyositis market growth over the forecast period

For instance, the drug Octagam 10% (Immune globulin (human)) approved for adult dermatomyositis causes headache, nausea, anaphylactic reactions, thrombosis, and in rare cases may cause side effects such as hemolytic anemia, aseptic meningitis syndrome, and transfusion-related acute lung injury (TRALI)

Some of the common side effects of Dermatomyositis drugs are: Pain and swelling at injection site, mild headache, fainting and dizziness, back pain, abdominal pain and muscle cramps, and minor chest pain.

Key Players

Major players operating in the global dermatomyositis market include AstraZeneca Plc., Bristol-Myers Squibb Company, Octapharma AG, Corbus Pharmaceuticals Holdings, Inc., CSL Limited, Ermium Therapeutics, Kezar Life Sciences Inc., Mallinckrodt Plc, Néovacs, Horizon Therapeutics plc, and Pfizer Inc.

Dermatomyositis is a rare condition that causes muscle inflammation. It presents with symmetric proximal muscle weakness, skin rash, and extra macular manifestations such as esophageal dysfunction and interstitial lung disease. Dermatomyositis is strongly associated with malignancy, especially in adults. Dermatomyositis is a systemic disorder that most frequently affects the skin and muscles but may also affect the joints, the esophagus, the lungs, and less commonly, the heart. Dermatomyositis presents with characteristic skin findings and symmetric proximal skeletal muscle weakness. It can also affect other organ systems such as the pulmonary, cardiovascular, and gastrointestinal systems. Various factors cause dermatomyositis such as genetic factors, immunologic factors, and environmental factors such as infections, drugs, and radiation.

Furthermore, there are three types of dermatomyositis namely, Adult Dermatomyositis, Dermatomyositis Sine Myositis, and Juvenile (Childhood) Dermatomyositis (JDMS). Dermatomyositis Sine Myositis is a term used to describe patients who are present with the dermatological features of dermatomyositis but an absence of associated muscle findings. Juvenile (childhood) dermatomyositis (JDMS) is an early onset form of dermatomyositis (DM), a systemic, autoimmune inflammatory muscle disorder with vasculopathy, characterized by proximal and symmetrical muscle weakness, evocative skin lesions, and systemic manifestations.

Market Dynamics

Market players are involved in the development of novel treatment for dermatomyositis which is expected to propel the market growth over the forecast period. For instance, in May 2022, Kezar Life Sciences, Inc., a clinical-stage biotechnology company, announced result from the PRESIDIO Phase 2 clinical trial of zetomipzomib (KZR-616) in patients with dermatomyositis (DM) and polymyositis (PM). The results of the PRESIDIO trial showed that most DM and PM patients saw clinically meaningful improvements in total improvement score (TIS).

Key features of the study:

  • This report provides an in-depth analysis of the global dermatomyositis market, market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global dermatomyositis market based on the following parameters – company highlights, types portfolio, key highlights, financial performance, and market strategies
  • Key companies covered as a part of this study include AstraZeneca Plc., Bristol-Myers Squibb Company, Octapharma AG, Corbus Pharmaceuticals Holdings, Inc., CSL Limited, Ermium Therapeutics, Kezar Life Sciences Inc., Mallinckrodt Plc., Néovacs, Horizon Therapeutics plc., and Pfizer Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global dermatomyositis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dermatomyositis market

Detailed Segmentation:

  • Global Dermatomyositis Market, By Type:
    • Adult Dermatomyositis
    • Dermatomyositis Sine Myositis
    • Juvenile (Childhood) Dermatomyositis (JDMS)
  • Global Dermatomyositis Market, By Treatment Type:
    • Anti-inflammatory Medication
    • Immunosuppressive Drugs
    • Immunoglobulin
    • Others (Plasma Exchange, Monoclonal antibody among others)
  • Global Dermatomyositis Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Dermatomyositis Market, By Region:    
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country/Region
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • AstraZeneca Plc.
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Bristol-Myers Squibb Company
    • Octapharma AG
    • Corbus Pharmaceuticals Holdings, Inc.
    • CSL Limited
    • Ermium Therapeutics
    • Kezar Life Sciences Inc.
    • Mallinckrodt Plc.
    • Néovacs, Horizon Therapeutics plc.
    • Pfizer Inc.

 “*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

Global dermatomyositis market is estimated to be valued at US$ 493.15 Million in 2022 and expected to exhibit a CAGR of 4.4% between 2022 and 2030.
Increasing funding by non-profit organizations, and product approvals and launches for the treatment of dermatomyositis are major growth driving factors for the market.
Adult Dermatomyositis is the major type segment, owing to increasing research and development for the treatment of dermatomyositis.
Side effects of dermatomyositis drugs is the major factor restraining the market growth.
Major players operating in the market include AstraZeneca Plc., Bristol-Myers Squibb Company, Octapharma AG, Corbus Pharmaceuticals Holdings, Inc., CSL Limited, Ermium Therapeutics, Kezar Life Sciences Inc., Mallinckrodt Plc., Néovacs, Horizon Therapeutics plc, and Pfizer Inc.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo